The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.
 
Takashi Sone
Speakers' Bureau - Chugai Pharma
 
Tomoyuki Araya
No Relationships to Disclose
 
Yuichi Tambo
No Relationships to Disclose
 
Kazuhiko Shibata
No Relationships to Disclose
 
Shingo Nishikawa
No Relationships to Disclose
 
Ryo Matsunuma
No Relationships to Disclose
 
Toshiyuki Kita
No Relationships to Disclose
 
Koji Kurokawa
No Relationships to Disclose
 
Hiroki Shirasaki
No Relationships to Disclose
 
Masaru Nishitsuji
No Relationships to Disclose
 
Josuke Hara
No Relationships to Disclose
 
Satoshi Nomura
No Relationships to Disclose
 
Hayato Koba
No Relationships to Disclose
 
Tamami Sakai
No Relationships to Disclose
 
Hirokazu Touge
No Relationships to Disclose
 
Yoshihisa Ishiura
No Relationships to Disclose
 
Shunichi Tamori
No Relationships to Disclose
 
Hideharu Kimura
No Relationships to Disclose
 
Taro Yoneda
No Relationships to Disclose
 
Kazuo Kasahara
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst)